Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Development of BTK Inhibitors: A Five-Year Update
Bruno Tasso, Andrea Spallarossa, Eleonora Russo, et al.
Molecules (2021) Vol. 26, Iss. 23, pp. 7411-7411
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Protein degraders enter the clinic — a new approach to cancer therapy
Deborah Chirnomas, Keith R. Hornberger, Craig M. Crews
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 4, pp. 265-278
Closed Access | Times Cited: 284
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 79
Amino-Pyrazoles in Medicinal Chemistry: A Review
Matteo Lusardi, Andrea Spallarossa, Chiara Brullo
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 7834-7834
Open Access | Times Cited: 37
Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
Ewa Robak, Tadeusz Robak
Journal of Clinical Medicine (2022) Vol. 11, Iss. 10, pp. 2807-2807
Open Access | Times Cited: 46
Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton’s Tyrosine Kinase for the Treatment of Lymphoma
Jingyu Zhang, Jinxin Che, Xiaomin Luo, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 9096-9125
Closed Access | Times Cited: 39
Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, et al.
Molecules (2023) Vol. 28, Iss. 5, pp. 2400-2400
Open Access | Times Cited: 33
The role of the methoxy group in approved drugs
Debora Chiodi, Yoshihiro Ishihara
European Journal of Medicinal Chemistry (2024) Vol. 273, pp. 116364-116364
Closed Access | Times Cited: 9
Bruton’s Tyrosine Kinase Inhibitors: Recent Updates
Amneh A Fares, Carlos Carracedo Uribe, Diana Martinez, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2208-2208
Open Access | Times Cited: 7
Pyrimidine scaffold dual‐target kinase inhibitors for cancer diseases: A review on design strategies, synthetic approaches, and structure–activity relationship (2018‒2023)
Minseok Song, Ahmed Elkamhawy, Woojeong Noh, et al.
Archiv der Pharmazie (2025) Vol. 358, Iss. 1
Closed Access
New drugs for multiple sclerosis: new treatment algorithms
Bruce Cree, Hans‐Peter Hartung, Michael Barnett
Current Opinion in Neurology (2022) Vol. 35, Iss. 3, pp. 262-270
Open Access | Times Cited: 27
The emerging role of targeted protein degradation to treat and study cancer
Maximillian H. Brodermann, Elizabeth Henderson, Rob S. Sellar
The Journal of Pathology (2024) Vol. 263, Iss. 4-5, pp. 403-417
Open Access | Times Cited: 4
Leveraging Synergistic Solubility in the Development of a Direct Isolation Process for Nemtabrutinib
Yonggang Chen, Luca Iuzzolino, Samantha A. Burgess, et al.
Organic Process Research & Development (2023) Vol. 27, Iss. 4, pp. 659-668
Closed Access | Times Cited: 8
Pharmacology of drugs used in autoimmune dermatopathies in cats and dogs: A narrative review
Heng L. Tham, Jennifer L. Davis
Veterinary Dermatology (2024) Vol. 35, Iss. 4, pp. 453-476
Open Access | Times Cited: 2
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia
Karan Chohan, Prashant Kapoor
Current Hematologic Malignancy Reports (2024) Vol. 19, Iss. 4, pp. 163-174
Closed Access | Times Cited: 2
Advanced approaches of developing targeted covalent drugs
Conghao Gai, Suzannah J. Harnor, Shihao Zhang, et al.
RSC Medicinal Chemistry (2022) Vol. 13, Iss. 12, pp. 1460-1475
Open Access | Times Cited: 12
Novel therapeutic opportunities for Toxoplasma gondii, Trichomonas vaginalis, and Giardia intestinalis infections
Francesca Arrighi, Arianna Granese, Paola Chimenti, et al.
Expert Opinion on Therapeutic Patents (2023) Vol. 33, Iss. 3, pp. 211-245
Closed Access | Times Cited: 6
Next-generation Bruton’s Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives
Debasis Das, Jingbing Wang, Jian Hong
Current Topics in Medicinal Chemistry (2022) Vol. 22, Iss. 20, pp. 1674-1691
Closed Access | Times Cited: 11
The potential of Bruton’s tyrosine kinase (BTK) inhibitors in the pharmacotherapeutic management of immune and dermatological disease
Henry Tseng, Dédée F. Murrell
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 12, pp. 1657-1665
Closed Access | Times Cited: 1
New small molecules in dermatology: for the autoimmunity, inflammation and beyond
Paulo Ricardo Criado, Daniel Lorenzini, Hélio Amante Miot, et al.
Inflammation Research (2023) Vol. 72, Iss. 6, pp. 1257-1274
Open Access | Times Cited: 4
Strategies for Competitive Activity‐Based Protein Profiling in Small Molecule Inhibitor Discovery and Characterization
He Zhu, Mona Sharafi, Wei Pin Teh, et al.
Israel Journal of Chemistry (2023) Vol. 63, Iss. 3-4
Closed Access | Times Cited: 2
Structural Complementarity of Bruton’s Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases
Asim Najmi, Neelaveni Thangavel, Anugeetha Thacheril Mohanan, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 3, pp. 400-400
Open Access | Times Cited: 2
Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature
Giuseppe Maggioni, Marny Fedrigo, Andrea Visentin, et al.
Current Oncology (2023) Vol. 30, Iss. 9, pp. 8255-8265
Open Access | Times Cited: 2
Unlocking potential inhibitors for Bruton's tyrosine kinase through in-silico drug repurposing strategies
Mohammed Alrouji, Lizy Sonia Benjamin, Fahad A. Alhumaydhi, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 2
Strategies for the Synthesis of Heterocycles and Their Applications
Premlata Kumari, Rohit Singh, Avneet Kaur, et al.
IntechOpen eBooks (2022)
Open Access | Times Cited: 4
Ibrutinib suppresses the activation of neutrophils and macrophages and exerts therapeutic effect on acute peritonitis induced by zymosan
Ran Guo, Zhiping Yan, Hanjing Liao, et al.
International Immunopharmacology (2022) Vol. 113, pp. 109469-109469
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top